Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor
Toyonaga T, Yamaguchi S, Hirata K, Kobayashi K, Manabe O, Watanabe S, Terasaka S, Kobayashi H, Hattori N, Shiga T, Kuge Y, Tanaka S, Ito YM, Tamaki N. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 44: 611-619. PMID: 27752745, DOI: 10.1007/s00259-016-3541-z.Peer-Reviewed Original ResearchConceptsProgression-free survivalExtent of resectionStandardized uptake valuePositron emission tomographyGross tumor volumeFMISO positron emission tomographyMagnetic resonance imagingKarnofsky Performance ScaleOverall survivalTumor volumeGlioblastoma patientsHypoxia volumeFDG positron emission tomographyFluorodeoxyglucose positron emission tomographyPotential prognostic factorsTotal lesion glycolysisMetabolic tumor volumeHypoxic volumeVolume of interestGadolinium-enhanced T1-weighted MR imagesReference regionT1-weighted MR imagesCytoreduction surgeryFree survivalPrognostic factors18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors
Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, Kobayashi K, Watanabe S, Shiga T, Terasaka S, Kobayashi H, Kuge Y, Tamaki N. 18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 43: 1469-1476. PMID: 26841941, DOI: 10.1007/s00259-016-3320-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrain NeoplasmsCerebellumFemaleHumansMaleMiddle AgedMisonidazoleNecrosisPositron-Emission TomographyConceptsPresence of necrosisBrain tumorsFMISO PETFMISO uptakeSevere hypoxiaFMISO PET/Brain tumor patientsPositron emission tomography (PET) tracerPositron emission tomographyEmission tomography tracerHistopathological necrosisPathological necrosisPoor prognosisSurgical strategyIntratumoral necrosisNeuroepithelial tumorsTumor resectionPathological diagnosisTumor patientsCerebellum ratioTreatment decisionsMethodsThis studyGroup 2Group 1Experienced neuropathologist